iRhythm (IRTC) Revenue & Revenue Breakdown
iRhythm Revenue Highlights
Latest Revenue (Y)
$492.68M
Latest Revenue (Q)
$147.54M
Main Segment (Y)
Commercial Payors
iRhythm Revenue by Period
iRhythm Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $492.68M | 19.90% |
2022-12-31 | $410.92M | 27.29% |
2021-12-31 | $322.82M | 21.74% |
2020-12-31 | $265.17M | 23.59% |
2019-12-31 | $214.55M | 45.66% |
2018-12-31 | $147.29M | 49.52% |
2017-12-31 | $98.51M | 53.75% |
2016-12-31 | $64.07M | 77.29% |
2015-12-31 | $36.14M | 66.17% |
2014-12-31 | $21.75M | - |
iRhythm Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $147.54M | -0.34% |
2024-06-30 | $148.05M | 12.22% |
2024-03-31 | $131.93M | -0.44% |
2023-12-31 | $132.51M | 6.35% |
2023-09-30 | $124.60M | 0.38% |
2023-06-30 | $124.13M | 11.39% |
2023-03-31 | $111.44M | -1.05% |
2022-12-31 | $112.62M | 8.42% |
2022-09-30 | $103.88M | 1.79% |
2022-06-30 | $102.05M | 10.47% |
2022-03-31 | $92.38M | 12.93% |
2021-12-31 | $81.80M | -4.25% |
2021-09-30 | $85.43M | 5.11% |
2021-06-30 | $81.28M | 9.38% |
2021-03-31 | $74.31M | -5.71% |
2020-12-31 | $78.81M | 9.54% |
2020-09-30 | $71.94M | 41.40% |
2020-06-30 | $50.88M | -19.92% |
2020-03-31 | $63.53M | 7.50% |
2019-12-31 | $59.10M | 5.62% |
2019-09-30 | $55.96M | 4.92% |
2019-06-30 | $53.33M | 12.96% |
2019-03-31 | $47.21M | 9.41% |
2018-12-31 | $43.16M | 13.26% |
2018-09-30 | $38.10M | 7.43% |
2018-06-30 | $35.47M | 16.04% |
2018-03-31 | $30.57M | 8.46% |
2017-12-31 | $28.18M | 12.57% |
2017-09-30 | $25.04M | 4.95% |
2017-06-30 | $23.85M | 11.27% |
2017-03-31 | $21.44M | 14.61% |
2016-12-31 | $18.70M | 11.47% |
2016-09-30 | $16.78M | 6.65% |
2016-06-30 | $15.73M | 22.41% |
2016-03-31 | $12.85M | 18.43% |
2015-12-31 | $10.85M | 16.16% |
2015-09-30 | $9.34M | - |
iRhythm Revenue Breakdown
iRhythm Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
Non-contracted Third-party Payors | $32.07M | $24.13M | $26.93M | $15.29M | $10.77M |
Healthcare Institutions | $71.00M | $59.77M | $57.50M | $41.40M | $43.02M |
Centers For Medicare And Medicaid | $122.41M | $103.03M | $44.53M | $72.54M | $58.92M |
Commercial Payors | $267.19M | $223.98M | $193.87M | $135.94M | - |
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Healthcare Institutions | $23.46M | $22.24M | $19.57M | $18.94M | $18.07M | $18.21M | $15.78M | $14.14M | $14.88M | $15.67M | $15.08M | $15.40M | $15.73M | $14.11M | $12.26M | $11.47M | $11.04M | $7.75M | $11.13M | $11.20M |
Centers For Medicare And Medicaid | $36.01M | $36.25M | $31.79M | $34.05M | $31.01M | $30.87M | $26.49M | $24.76M | $20.06M | $10.95M | $12.41M | $10.99M | $10.18M | $21.52M | $19.98M | $13.72M | $17.32M | $16.34M | - | - |
Non-Contracted Third-Party Payors | $10.81M | $10.30M | $8.80M | $8.20M | $7.72M | $7.26M | $5.72M | $6.17M | $5.49M | $7.35M | $6.55M | $5.28M | $4.61M | $2.87M | $3.38M | - | - | - | - | - |
Commercial Payors | $77.26M | $79.25M | $71.77M | $70.63M | $67.34M | $67.32M | $61.91M | $60.77M | $56.02M | $55.45M | $51.75M | $47.70M | $49.94M | $49.63M | $46.59M | $41.37M | $36.32M | $26.54M | $31.71M | $28.84M |
Non-contracted Third-party Payors | - | - | - | - | - | - | - | $6.75M | $7.75M | $4.44M | $2.72M | - | - | - | - | - | - | - | - | - |
iRhythm Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BRKR | Bruker | $2.96B | $800.70M |
ITGR | Integer | $1.60B | $746.27M |
CNMD | CONMED | $1.24B | $316.70M |
LIVN | LivaNova | $1.15B | $318.11M |
IRTC | iRhythm | $492.68M | $147.54M |
GKOS | Glaukos | $314.71M | $95.69M |
FNA | Paragon 28 | $216.39M | $61.02M |
KIDS | OrthoPediatrics | $148.73M | $52.80M |
SRDX | Surmodics | $132.58M | $30.34M |
SGHT | Sight Sciences | $81.06M | $21.37M |
NPCE | NeuroPace | $65.42M | $18.12M |
OFIX | Orthofix Medical | $100.00K | $198.62M |
IRTC Revenue FAQ
What is iRhythm’s yearly revenue?
iRhythm's yearly revenue for 2023 was $492.68M, representing an increase of 19.90% compared to 2022. The company's yearly revenue for 2022 was $410.92M, representing an increase of 27.29% compared to 2021. IRTC's yearly revenue for 2021 was $322.82M, representing an increase of 21.74% compared to 2020.
What is iRhythm’s quarterly revenue?
iRhythm's quarterly revenue for Q3 2024 was $147.54M, a -0.34% decrease from the previous quarter (Q2 2024), and a 18.41% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $148.05M, a 12.22% increase from the previous quarter (Q1 2024), and a 19.27% increase year-over-year (Q2 2023). IRTC's quarterly revenue for Q1 2024 was $131.93M, a -0.44% decrease from the previous quarter (Q4 2023), and a 18.39% increase year-over-year (Q1 2023).
What is iRhythm’s revenue growth rate?
iRhythm's revenue growth rate for the last 3 years (2021-2023) was 52.62%, and for the last 5 years (2019-2023) was 129.63%.
What are iRhythm’s revenue streams?
iRhythm's revenue streams in c 23 are Non-contracted Third-party Payors, Healthcare Institutions, Centers For Medicare And Medicaid, and Commercial Payors. Non-contracted Third-party Payors generated $32.07M in revenue, accounting 6.51% of the company's total revenue, up 32.89% year-over-year. Healthcare Institutions generated $71M in revenue, accounting 14.41% of the company's total revenue, up 18.79% year-over-year. Centers For Medicare And Medicaid generated $122.41M in revenue, accounting 24.85% of the company's total revenue, up 18.81% year-over-year. Commercial Payors generated $267.2M in revenue, accounting 54.23% of the company's total revenue, up 19.29% year-over-year.
What is iRhythm’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of iRhythm was Commercial Payors. This segment made a revenue of $267.2M, representing 54.23% of the company's total revenue.